2020
FluoGuide’s primary focus is to maximize surgical outcomes in oncology. The Company’s first product, FG001, is designed...
”We are very pleased with our development and our shareholders’ interest in FluoGuide. The proceed from the warrants will...
Warrants TO 1 that has not been subscribed for shares by Thursday 7 May 2020 or sold by Tuesday 5 May 2020 will expire and are thereafter...
29 April, 2020
FluoGuide A/S interview by BioStock Live now available
To watch the interview and presentation, please follow link. (https://fluoguide.com/investor/calendar-events/) For more information...
29 April, 2020
Members of the board and management exercise warrants and subscribe for shares in FluoGuide A/S
The FluoGuide warrants of series TO 1 that was issued in connection with FluoGuide’s issue of units, prior to listing on Spotlight...
23 April, 2020
Communique from the Annual General Meeting in FluoGuide A/S
1. ELECTION OF CHAIRMAN OF THE GENERAL MEETING
Lawyer Anders Rubinstein was elected as chairman of the meeting. The chairman ascertained...
23 April, 2020
FluoGuide secures a pipeline of uPAR targeting products
The invention comes from research, led by Professor Andreas Kjær and funded by a Grand Solutions Grant from Innovation Fund Denmark...
22 April, 2020
FluoGuide participate on BioStock Live tomorrow, Thursday 23 April 2020 at 13.00 (CEST)
Date: Thursday, April 23 Time: The live broadcast starts at 13.00 (CEST) Location: Follow the broadcast here The presentation will...
16 April, 2020
The exercise period for FluoGuide warrants TO1 begins today
FluoGuide issued units in its IPO in 2019. Each unit consisted of three shares and one free warrant TO 1. During the exercise period...